SeaStar Medical Raises $3.3M via Warrant Exercise

  • SeaStar Medical exercised warrants for 854,002 shares at a reduced price of $3.866 per share, raising $3.3M gross.
  • The warrants were originally issued in June, July, and August 2025 with exercise prices ranging from $6.38 to $7.62.
  • In exchange, SeaStar issued new warrants for up to 1,708,004 shares at $3.616 per share.
  • Proceeds will be used for general corporate purposes, including working capital and capital expenditures.
  • The offering is expected to close on October 5, 2026.

SeaStar Medical's warrant exercise underscores its focus on securing non-dilutive financing to support its commercial-stage operations. The move comes as the company advances its SCD therapy through pivotal trials, aiming to address critical unmet needs in acute kidney injury. The $3.3M raise, though modest, provides a financial buffer amid the high costs of clinical development and regulatory approvals in the biotech sector.

Financial Flexibility
How SeaStar Medical will allocate the $3.3M proceeds to support its operations and growth initiatives.
Market Conditions
Whether the reduced exercise price reflects broader market challenges or strategic adjustments.
Regulatory Pathway
The pace at which SeaStar Medical advances its NEUTRALIZE-AKI trial and secures additional FDA approvals.